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Summary The risk of second primary malignancy was assessed in a population-based cohort study of all
persons registered with Hodgkin's disease (n =2,970), ovarian cancer (n = 11,802) and testicular cancer
(n=2,013) in the South Thames Cancer Registry during the period 1961-80, to identify for further study those
second malignancies which might be treatment-related.
A total of 244 second malignancies was observed. After adjustment for age, sex and calendar period, the
relative risk of any second malignancy was 1.4 (90% confidence interval (CI) 1.1-1.7) after Hodgkin's disease,
1.1 (90% CI 1.0-1.2) after ovarian cancer and 0.7 (90% CI 0.5-1.0) after testicular cancer. In particular, the
relative risk for leukaemia was 11.9 after Hodgkin's disease, 3.7 after ovarian cancer and 2.5 after testicular
cancer. Excess risks were also observed for cancers of the cervix and lung after Hodgkin's disease, for cancers
of the breast, lung and rectum after ovarian cancer, and for contralateral testicular cancer. Confounding by
social class or smoking does not explain these observations. The excess risks of leukaemia and of second
cancer were higher in patients first diagnosed with Hodgkin's disease and ovarian cancer in the 1970s than for
those first diagnosed in the 1960s. Increased use of multiple-agent chemotherapy regimes for these tumours in
the 1970s may have contributed to these increases in excess risk.
As cancer treatment and survival improve, the risk of
developing a second primary malignancy is becoming
increasingly important in planning the management of a
patient's first cancer (Anon, 1985; Whitehouse, 1985). An
increased incidence of acute and non-lymphocytic leukaemia
following treatment of a previous malignancy with chemo-
therapy or radiotherapy has been well documented (IARC,
1982; Curtis et al., 1984), and solid tumours in individuals
with a previous haemopoietic neoplasm have also been
observed (Krause et al., 1985). Some multiple primary
malignancies may reflect a genetic predisposition to cancer
(Meadows & Hobbie, 1986) or a common aetiology, but
there is now sufficient evidence for widely-used alkylating
agents such as chlorambucil, cyclophosphamide, melphalan
and treosulphan to be classified as carcinogenic in humans
(IARC, 1982; Schmahl, 1987), and it is therefore important
that a quantitative assessment is made of the degree of
carcinogenicity of such drugs (Anon, 1984).
Cytotoxic therapy has been used for about 40 years in the
treatment of cancer, initially as single agents for palliation of
advanced disease, and with increasing frequency since the
mid-1960s, in various combinations, often as the mainstay of
an attempt at radical cure. Chemotherapy has been used
particularly for the treatment of Hodgkin's disease (McVie &
Somers, 1985; Kennedy et al., 1985) and cancers of the
ovary (Reimer et al., 1977) and testis (Newlands et al., 1983).
Chemotherapy has also been used as adjuvant therapy in
patients with resectable cancers, particularly of the breast
(National Institutes of Health, 1986) and gastrointestinal
tract (Boice et al., 1983). Patients selected for adjuvant
cancer chemotherapy are often those considered to have a
better prognosis, and possible induction of second cancers by
such treatment is therefore of particular concern. In
addition, however, cytotoxic drugs have been widely used as
immunosuppressants in the treatment of non-neoplastic
conditions such as rheumatoid arthritis, multiple sclerosis,
psoriatic nephropathy and in renal transplantation
(Grunwald & Rosner, 1979; Kinlen et al., 1979). Since many
patients receiving cytotoxic drugs, particularly children
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treated for cancer, will survive long enough for a treatment-
induced malignancy to become manifest, reliable data are
needed to establish which drugs are carcinogenic, either
alone or in combination, which patients may be most at risk,
and what the magnitude of that risk may be (Anon, 1984;
Whitehouse, 1985).
We have used data from the South Thames (now Thames)
Cancer Registry to estimate the risk of second primary
malignancy in patients with Hodgkin's disease, cancer of the
ovary and cancer of the testis, as a first step in identifying
for more detailed study second malignancies which might be
treatment-related. The data analysed here form part of a
collaborative study, sponsored by the International Agency
for Research on Cancer, Lyon, in which the risk of second
primary malignancy is being assessed by pooling data from
eleven cancer registries on over 133,000 patients with these
index tumours (Kaldor et al., 1987). However, treatment
practices vary between and within countries, and it is
additionally of interest to ascertain which second primary
malignancies are particularly prevalent locally, and to
present some further detail beyond the scope of the
international summary paper.
Study population and methods
The study population comprised all patients registered with
Hodgkin's disease, cancer of the ovary or cancer of the testis
(index tumours) in the South Thames Cancer Registry
during the period 1961-80, and whose usual place of
residence was in the territory covered by the registry, which
includes Greater London south of the River Thames, and
the counties of Kent, Surrey and Sussex. About 30,000
tumours are registered each year among a population of
more than six million people. During the study period,
registry staff regularly followed up all patients, even if they
had left the territory, by contacting the hospital or general
practitioner to obtain information about subsequent primary
cancers or death. In addition, all patients registered since 1
January 1971 have been flagged at the National Health
Service Central Register (NHSCR) in Southport: when the
patient dies, a copy of the death certificate is sent to the
cancer registry. Complete follow-up until death is thus
achieved for virtually all patients. The analysis presented
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here is based on the follow-up of all patients to 31 December
1981.
The type of initial treatment given (chemotherapy, radio-
therapy, surgery, or some combination) is recorded at
registration for more than 90% of tumours, but no details of
this treatment or of any later treatment are recorded, so the
effect of the treatment for each index tumour on second
cancer risk could not be examined directly in the registry
material. Instead, and in view of the widespread replacement
of single agent chemotherapy by multiple-agent regimes
towards the end of the 1960s (McVie & Somers, 1985), we
examined second cancer risk separately for index tumours
first treated in the 1960s (1961-69) and in the 1970s (1970-
80), in order to determine if any major change in second
cancer risk had occurred among patients treated with a first
cancer in these two decades. Changes in the distribution of
treatment types between the two periods were also examined.
More precise estimates of risk in relation to specific
treatment regimes will be obtained in later case-control
studies.
All notifications of cancer received by the registry are
checked against an alphabetic index to avoid duplicate
registration of a single tumour. This check also serves to
identify a second primary cancer for the same person. More
than 80% of all tumours are histologically confirmed. This
proportion is higher among second tumours: a second cancer
will normally be accepted as a new primary cancer only if
both the site and the histology are distinct from that of the
first cancer. For second cancers at the same site as the first
cancer, or those at a different site but with the same
histology as the first cancer, the new cancer will be registered
as a second primary only if the hospital record or pathology
report explicitly states that it is a new primary, distinct from
the previous cancer. Doubtful cases are referred to the
consultant in charge of the patient. Second cancers in paired
organs are accepted on the same basis. All cancers were
coded to the eighth revision of the International Classifi-
cation of Diseases (ICD-8) (World Health Organization,
1967).
Patients were excluded from the analysis if they had had
another tumour registered either before or at the same time
as the index tumour, or if their index tumour had been
registered at death (no follow-up) or at age 85 years or
*more. A few patients registered before 1971 and for whom
active follow-up failed to provide any information were also
excluded: these patients are described as 'lost to follow-up at
registration'.
Each eligible subject was included in the analysis from the
date of first treatment for the index tumour until the earliest
of the following events: second cancer registration (if any),
85th birthday (censoring age), death, or the end of the study
(31 December 1981). Patients registered before 1971 were
retained in the analysis until the day on which they were last
known to be alive; those registered in 1971 or later, who
were all flagged at NHSCR, were assumed to be alive unless
the cause and date of death had been recorded. Second
tumours occurring at age 85 or over were excluded because
histological confirmation of cancer is less often available for
*this age-group, and tumours are more often registered at
death.
The observed number of second tumours was compared
with an expected number derived by assuming that second
primary tumours arise in the study population with the same
frequency as do first primary- cancers among the general
population of the registry area. Person-years at risk were
tabulated for each index tumour by sex, five-year age group,
and for each of two calendar periods. Expected numbers of
second cancers at each site were calculated by multiplying
the person-years at risk by the corresponding age-, sex- and
period-specific cancer incidence rate; incidence rates for the
period 1967-71 (Payne, 1976) were applied to person-years
accrued up to 1972 and those for 1973-77 (Skeet, 1982) to
person-years accrued from 1973. The ratio of observed to
expected numbers was taken as an estimate of the incidence
rate ratio (relative risk (RR)) of second tumours in the study
population, adjusted for age, sex and calendar period (Berry,
1983; Breslow, 1984). The statistical significance of any
excess of second tumours was derived by assuming the
observed number to be drawn from a Poisson distribution
with mean equal to the expected number: tests were one-
sided, in the direction of the observed difference. These
calculations were done separately for index tumours
diagnosed in the 1960s and the 1970s, using the program
PYRS (Coleman et al., 1986). Ninety per cent confidence
intervals for the RR were calculated (Rothman & Boice,
1982).
Second cancer risk was only assessed at one or more years
after diagnosis of the index tumour. Close medical
surveillance during treatment may lead to earlier detection of
other malignancies already present, a form of detection bias.
Mis-diagnosis of a metastasis as a new primary cancer is also
more likely during the early period after diagnosis of the
index primary. Second tumours and person-years at risk
arising less than one year after the index tumour were
therefore excluded from analysis. It should be noted that this
may lead to underestimation of the true risk of second
cancer in the period shortly after diagnosis of the first, but




Of 3,138 registered cases of Hodgkin's disease, 168 (5%) were
excluded (Table I). More than half the subjects were under
45 years of age at diagnosis. Table IIA shows how the
number still alive and at risk of a second tumour fell with
time since diagnosis, largely as a result of mortality from the
index tumour. Subjects were followed up for a total of 14829
(mean 5.0) person-years at risk of a second tumour until the
end of 1981 (Table IIB). Thirty-nine per cent (1153) survived
without developing a new tumour to the fifth anniversary of
their first treatment. The proportion of patients treated with
chemotherapy alone increased from 20% in the 1960s to
28% in the 1970s (Table IIC).
Among the 2,970 eligible patients, 58 second primary
malignancies were observed at least one year after diagnosis
of the Hodgkin's disease, whereas 41.85 would have been
expected, a 39% excess (RR= 1.4, 90% CI 1.1-1.7; see Table
III). Most of the excess was due to leukaemia and lung
cancer. The excess of leukaemia was greater than ten-fold
(10 vs. 0.84, RR= 11.9, CI 6.5-20.2). Lung cancer was twice
as common as expected (20 vs. 9.38, RR=2.1, CI 1.4-3.1),
Table I Exclusions from analysis
Index primary cancer
Reasonfor Hodgkin's
exclusion disease Ovary Testis
Total tumours 3,138 13,044 2,080
Prior/synchronous
tumour 69 679 40
Registered at death 65 376 3
Registered at 85+ 13 140 5
Lost to follow-up
at registrationa 21 47 16
Faulty data - - 3
Total exclusions 168 (5%) 1,242 (10%) 67 (3%)
Subjects analysed 2,970 11,802 2,013
aRegistered before 1971 and lost to follow-up: see text.COHORT STUDY OF SECOND PRIMARY MALIGNANCY 351
Table II Characteristics of study population
A No. of subjects still alive and at risk of a second tumour, by time
since diagnosis of index tumour
Time since
diagnosis (yrs) Hodgkin's disease Ovary Testis
1-4 2,160 5,341 1,627
5-9 1,153 1,984 1,004
10-14 526 1,057 607
15-19 173 492 281
20+ 23 79 38
B Person-years at risk of a second tumour, by time since diagnosis
of index tumour.
Time since
diagnosis (yrs) Hodgkin's disease Ovary Testis
<1 2,458 7,559 1,788
1-4 6,296 11,831 4,970
5-9 4,036 7,231 3,971
10-14 1,604 3,671 2,127
15-19 425 1,243 778
20+ 10 37 21
Total (excluding
first year) 12,371 24,013 11,867




1960's 1970's 1960's 1970's 1960's 1970's
Chemotherapy
alonea 20 28 22 31 3 7
Radiotherapy
alonea 36 35 25 18 74 66
Both 34 27 11 15 10 16
Surgery alone 2 1 24 20 10 8
Not stated 7 9 18 16 3 3
aTreatment category includes patients treated with and without
surgery.
and the relative risk was greater in women (3.5) than in men
(1.9). Most of the excess lung cancers occurred within 10
years of diagnosis (17 vs. 7.41 within 10 years; 3 vs. 1.98 at
10 or more years). Among the women with Hodgkin's
disease, there was a five-fold excess of cervix cancer (4 vs.
0.80, CI 1.7-11.4), but we observed only half as many breast
cancers as expected (2 vs. 4.39; RR=0.5, CI 0.1-1.4). There
was* no excess of non-Hodgkin's lymphoma, and no
significant deficit of second cancer at any site.
The overall risk of second cancer following Hodgkin's
disease increased from 1.2 for patients treated in the 1960s to
1.6 for those treated in the 1970s (Table III). For men, the
leukaemia risk more than doubled, from seven-fold to
twenty-fold; the risk for women was about ten-fold, but with
little change over time. An increase in risk between the 1960s
and 1970s was seen for most sites of second cancer.
Ovarian cancer
Of 13,044 women with cancer of the ovary, almost 10%
(1242 women) were excluded from analysis (Table I); more
than half of these (679, 5.2% of cohort) had had a previous
tumour or a tumour registered in the same calendar year as
the ovarian cancer. Of the 11,802 women analysed, fewer
than half survived to the first anniversary of treatment
(Table IIA), and less than a fifth (17%) survived five years.
The women were followed for a total of 31,572 (mean 2.7)
person-years at risk of a second tumour (Table IIB). The
proportion of women treated with chemotherapy alone arose
from 22% in the 1960s to 31% in the 1970s (Table IIC).
We observed 170 second malignancies among these women
at least one year after their ovarian cancer, against 152.9
expected (Table IV), an 11% excess (RR=1.1, CI 1.0-1.3).
Cancer of the breast accounted for more than half the
overall excess of second cancer (47 vs. 38.1, RR=1.2, CI
1.0-1.6). Women treated for ovarian cancer in the 1970s had
a higher risk of subsequent breast cancer (RR= 1.4) than
women treated in the 1960s (RR = 1.1). The youngest women
with ovarian cancer appeared to have a much greater risk of
subsequent breast cancer (Table V): among women aged less
than 40 at ovarian cancer, the risk was five-fold (3 vs. 0.58,
RR=5.2, CI 1.7-12.3), but for women aged 40 and over, the
observed excess was small (44 vs. 37.54, RR= 1.2), and
compatible with an unchanged risk. Although the numbers
are small, there is a marked decline of breast cancer risk
with increasing age at ovarian cancer (X2 for trend 4.9,
P=0.01). All the excess breast cancers arose in the first ten
years of follow-up (41 vs. 29.22 within 10 years; 6 vs. 8.90 at
ten or more years), and most of the significant downward
trend in breast cancer risk with increasing age at ovarian
cancer is contributed by these early second breast cancers.
There was a greater than three-fold excess of leukaemia
following ovarian cancer (10 vs. 2.7; RR=3.7; CI 2.0-6.3).
The relative risk of leukaemia increased markedly from 1.2
for women treated for ovarian cancer in the 1960s to 8.0 for
those treated in the 1970s. Rectal cancer occurred more
often than expected (12 vs. 7.2, RR= 1.7, CI 1.0-2.7), as did
cancers of the lung and colon. We observed only one
contralateral ovarian cancer more than five years after the
first, against 8.7 expected, the only second cancer in
significant deficit. This deficit is more apparent than real,
however, since many women will have had both ovaries
removed at surgery for their ovarian cancer, but the registry
Table III Relative risk (RR) of second malignancy by calendar period of Hodgkin's disease
Period ofdiagnosis ofHodgkin's disease
1961-69 1970-80 1961-80
No. of persons 1,331 1,639 2,970
Person-years at riska 6,423 5,948 12,371
90% confidence
Second malignanciesb Obs Exp RR Obs Exp RR Obs Exp RR interval
Leukaemia 4 0.47 8.5 6 0.37 16.2 10 0.84 11.9 6.5-20.2
Lung 7 5.28 1.3 13 4.10 3.2 20 9.38 2.1 1.4- 3.1
Breast (F) 1 2.33 0.4 1 2.06 0.5 2 4.09 0.5 0.1- 1.5
Cervix (F) 2 0.46 4.4 2 0.34 5.9 4 0.80 5.0 1.7-11.4
All sites 27 23.03 1.2 31 18.75 1.6 58 41.78 1.4 1.1- 1.7
aTo 31 December 1981, excluding each person's first year of follow-up; bObs =observed,
Exp =expected.352 M.P. COLEMAN et al.
Table IV Relative risk (RR) of second malignancy by calendar period of ovarian cancer
Period ofdiagnosis ofovarian cancer
1961-69 1970-80 1961-80
No. of women 5,321 6,481 11,802
Person-years at riska 15,202 8,811 24,013
90% confidence
Second malignanciesb Obs Exp RR Obs Exp RR Obs Exp RR interval
Leukaemia 2 1.67 1.2 8 1.00 8.0 10 2.67 3.7 2.0-6.4
Lung 13 9.56 1.4 6 5.97 1.0 19 15.53 1.2 0.8-1.8
Breast 26 23.56 1.1 21 14.55 1.4 47 38.11 1.2 1.0-1.6
Colon 10 8.80 1.1 5 5.13 1.0 15 13.93 1.1 0.7-1.7
Rectum 5 4.53 1.1 7 2.66 2.6 12 7.19 1.7 1.0-2.7
All sites 96 90.06 1.1 74 62.88 1.2 170 152.94 1.1 1.0-1.3
aTo 31 December 1981, excluding each person's first year of follow-up; bObs=observed,
Exp=expected.
Table V Second breast cancer, by age at ovarian cancer and time since ovarian cancer
Time since diagnosis ofovarian cancer (years) Allperiods
1-4 5-9 10-21 1-21
No. of womena 5,341 1,984 1,057 5,341
Person-years at riskb 11,831 7,231 4,951 24,013
90% confidence
Obs Exp Obs Exp Obs Exp Obs Exp RR interval
Age at ovarian
cancer (years)
<30 1 0.01 - 0.01 - 0.00 1 0.02 50.0 2.6-237.2
30-39 1 0.27 1 0.19 - 0.10 2 0.56 3.6 0.6- 11.2
40-49 6 2.53 1 1.25 - 0.70 7 4.48 1.6 0.7- 2.9
50-59 8 5.22 4 3.08 1 1.82 13 10.12 1.3 0.8- 2.0
60-69 9 5.36 3 3.65 3 2.99 15 12.00 1.2 0.8- 1.9
70-84 2 4.31 5 3.34 2 3.29 9 10.94 0.8 0.4- 1.4
All ages (<85) 27 17.70 14 11.52 6 8.90 47 38.12 1.2 1.0- 1.6
RR 1.53 1.22 0.67
aNo. of women still alive and at risk of breast cancer at the beginning
December 1981; excluding each woman's first year of follow-up.
records do not contain the data needed to obtain the
appropriate risk (for women who still have at least one
ovary). If we exclude ovarian cancer as a second tumour for
this reason, the overall picture changes only slightly (169 vs.
144.2, RR= 1.2, CI 1.0-1.3).
Testicular cancer
Of 2,080 men registered with testicular cancer, 67 (3%) were
excluded (Table I). Less than half of these (1,004, 48%) were
still alive and at risk of a second cancer five years after
treatment (Table IIA). The cohort was followed up for a
total of 13,655 (mean 6.8) person-years at risk to the end of
1981 (Table IIB). Three per cent of men with testicular
cancer were treated with chemotherapy alone in the 1960s,
compared to 7% in the 1970s (Table IIC).
We observed 27 second cancers one or more years after
testicular cancer, fewer than the 36.36 expected (RR=0.7, CI
0.5-1.0) (Table VI). The only second tumours which
occurred in significant excess were contralateral testicular
tumours, of which there were five, each with a different
histology from the first tumour. The overall risk was 8.1 (CI
3.6-16.0). The excess of leukaemia was small (2 vs. 0.80),
and there was no excess of lung cancer. No significant deficit
of second cancer was observed at any site. Apart from
cancers of the contralateral testis, for which the risk rose
from 2.9 to 14.3 over the two decades, there was no general
increase in second cancer risk between testicular cancer
patients treated in the 1960s and those treated in the 1970s
(Table VI).
of successive time intervals; bTo 31
Leukaemia as a second malignancy
Leukaemia was consistently observed more often than
expected after each of the three index tumours, in both
decades, and in each sex (Table VII). Among the 18,262
subjects in all three cohorts, 22 second leukaemias were
observed, against 4.41 expected, a five-fold overall risk
(RR=5.0, CI 3.4-7.1). Among the different types of
leukaemia, the smallest excess risk was for lymphatic
leukaemia (RR = 2.5). Leukaemia risk was greater than ten-
fold for patients with Hodgkin's disease (RR= 11.9, CI 6.5-
20.2), and more than three-fold for women with ovarian
tumours (RR= 3.7, CI 2.0-6.3); the two-fold excess for men
with testicular cancer was not significant. Fifteen (68%) of
the 22 second leukaemias were acute, eleven (50%) of them
acute myeloid leukaemia; only two (10%) were chronic
lymphatic leukaemia.
Discussion
New primary cancers are perhaps the most serious late
complication of cytotoxic chemotherapy for cancer or non-
neoplastic disease (Calabresi, 1983; Anon, 1984; Whitehouse,
1985; Meadows & Hobbie, 1986; Kinlen et al., 1979).
Previous studies have considered mainly the risk of acute
leukaemia after Hodgkin's disease (see Grunwald & Rosner,
1982) and ovarian cancer (Reimer et al., 1977; Greene et al.,
1982; Haas et al., 1987), but the risk of other second cancers
has also been examined among patients with Hodgkin's
disease (Brody & Schottenfeld, 1980; Boivin & Hutchison,COHORT STUDY OF SECOND PRIMARY MALIGNANCY 353
Table VI Relative risk (RR) of second malignancy by calendar period of testicular cancer
Period ofdiagnosis oftesticular cancer
1961-69 1970-80 1961-80
No. of men 774 1,239 2,013
Person-years at riska 7,240 4,627 11,867
90% confidence
Second malignanciesb Obs Exp RR Obs Exp RR Obs Exp RR interval
Leukaemia 2 0.51 3.9 0 0.29 0.0 2 0.80 2.5 0.4- 7.9
Lung 6 7.42 0.8 1 3.47 0.3 7 10.89 0.6 0.3- 1.2
Testis 1 0.34 2.9 4 0.28 14.3 5 0.62 8.1 3.2-17.0
All sites 19 24.10 0.8 8 12.10 0.7 27 36.20 0.7 0.5- 1.0
aTo 31 December 1981, excluding each person's first year of follow-up; bObs=observed,
Exp =expected.
Table VII Relative risk (RR) of second leukaemiaa by type of index primary tumour
Hodgkin's
disease Ovary Testis All types
90% confidence
ICD-8 Leukaemia type Obs Exp Obs Exp Obs Exp Obs Exp RR interval
204 Lymphoid 1 0.34 3 0.96 0 0.29 4 1.59 2.5 0.9- 5.8
205 Myeloid 7 0.41 4 1.34 0 0.40 11 2.15 5.1 2.9- 8.5
206 Monocytic 2 0.04 0 0.13 0 0.03 2 0.20 10.0 1.8-31.5
207 Other 0 0.09 3 0.29 2 0.09 5 0.47 10.6 4.2-22.4
204-7 All types 10 0.88 10 2.72 2 0.81 22 4.41 5.0 3.4- 7.1
RR 11.4 3.7 2.5
(90% confidence (6.2-19.3) (2.0-6.2) (0.4-7.8)
interval)
aObs=observed, Exp=expected.
1984; Henry-Amar, 1983) and testicular cancer (Hay et al.,
1984; Maatman et al., 1984; Dieckmann et al., 1986). Most
of these studies were based on a series of several hundred or
a few thousand patients recruited from one or several
referral hospitals, although Henry-Amar's (1983) study
included patients in a multi-centre trial. Risk estimates for
leukaemia following Hodgkin's disease, not always adjusted
for age, sex and time, ranged from 3- to 17-fold, but were
often based on small numbers of cases. Leukaemia risk has
been strongly associated with chemotherapy in these reports:
45 of 46 second leukaemias in the studies reviewed by Boivin
and Hutchison (1984) arose in patients given chemotherapy
with their first course of treatment, while the risk in patients
treated without chemotherapy showed little increase over
background rates.
This study at the South Thames Cancer Registry has
shown that although the highest risk of second primary
malignancy following treatment for Hodgkin's disease is for
acute leukaemia, some solid tumours also occur in excess.
Lung cancer risk was twice as high as expected after
Hodgkin's disease, and there was a five-fold excess of cervix
cancer. Both results are statistically significant, although the
cervix result is based on only four observed cases. Smoking
seems unlikely to be an important confounding factor in
either case, since it is not known to be associated with
Hodgkin's disease, and confounding is also an unlikely
explanation for risks of this magnitude. Nor can the excess
of cervical cancer be explained by social class, since the
social class gradient for Hodgkin's disease, which is more
common in higher socio-economic groups, is the reverse of
that for cervical cancer.
The relative risk of any second primary malignancy after
Hodgkin's disease increased from 1.2 to 1.6 between the
1960s and the 1970s, and the relative risk of leukaemia
doubled from 8-fold to 16-fold. Increases in risk were seen
for most individual sites of second cancer, although the
numbers are mostly too small to reach statistical significance.
This is not the result of improvement in survival in the later
period, since the risk estimates take precise account of each
subject's observed survival. The proportion of patients
treated only with chemotherapy rose by half among men and
by a quarter among women between the two decades
covered by this study, and it is at least plausible that the
increases in risk resulted from the use of more aggressive,
multi-agent regimes which were introduced for Hodgkin's
disease in the late 1960s and early 1970s.
The overall excess of second malignancy after cancer of
the ovary is small, the largest contributions coming from
breast cancer and leukaemia. The relative risk of leukaemia
increased markedly between the decades, and there were
smaller increases in risk for cancers of the rectum and breast.
The proportion of women initially treated only with
chemotherapy increased from 22% to 31% between the same
periods. The mean duration of follow-up for women with
ovarian cancer first seen in the 1970s was less than two
years; the latency of most solid tumours is likely to be longer
than this, and the possibility of a greater risk for solid
tumours after longer periods of follow-up cannot be
excluded for women treated in the 1970s.
The excess risk of breast cancer after cancer of the ovary
was largely confined to women under the age of 40 at
diagnosis of ovarian cancer, and the steep decrease in risk
with age suggests that this may be due to higher
susceptibility to radiation and chemical carcinogenesis in the
breast tissue of younger women (Boice & Monson, 1977).
No significant excess of secolid cancer was seen among
men with cancer of the testis, except for contralateral
testicular cancer. The overall risk of a second cancer of the
testis was 8.1, increasing sharply from three-fold for men
treated in the 1960s to 14-fold for those treated in the 1970s.354 M.P. COLEMAN et al.
Relatively few men with testicular cancer were treated with
chemotherapy alone in either time period.
The excess risk of second leukaemia would undoubtedly
have been even greater if all leukaemias diagnosed after a
previous cancer had been registered. We have good evidence
(Dr S. Nayfield, personal communication) that such
leukaemias were often not registered at South Thames,
because even if they were treated clinically as a new
leukaemia, this diagnosis was not always explicitly recorded.
This was particularly so if they supervened in patients with
Hodgkin's disease, in which leukaemia or a leukaemic phase
has often been considered to be part of the natural history
of the disease (Reimer et al., 1977). However, the striking
increase in the risk of second leukaemia following Hodgkin's
disease seen in the twenty years covered by this study
suggests that the two diseases are probably quite distinct,
and that the association between them requires a different
explanation.
This study confirms that significant excess risks of second
malignancy - both leukaemia and solid tumours - occur in
patients with Hodgkin's disease and cancers of the ovary or
testis, although the excess of solid tumours in testicular
cancer patients was confined to contralateral tumours of the
testis. Leukaemia risk was increased five-fold, and more than
ten-fold among patients with Hodgkin's disease. There is a
tendency towards higher excess risks of second malignancy
in patients with Hodgkin's disease and ovarian cancer who
were first treated in the 1970s, when cytotoxic agents were
used as the mainstay of treatment more extensively than in
the 1960s. No such general pattern was observed for men
with testicular cancer; cis-platinum was introduced in the
UK in 1978, and radiotherapy was the principal treatment
recorded at registration in both time periods, but the risk of
a second testicular cancer did increase between the decades.
These patterns of risk suggest that at least part of the
increase in second cancer risk observed between patients first
treated for Hodgkin's disease and ovarian cancer in the
1960s and those treated in the 1970s may be related to
chemotherapy. Case-control studies are now being carried
out on lung cancer following Hodgkin's disease, and on
leukaemia following each of the three index tumours
considered here, and the detailed treatment records will
enable any risks associated with chemotherapy to be
carefully examined.
Despite widespread use of cytotoxic drugs in cancer
therapy, the development of a second primary malignancy
still remains an uncommon late complication, arising in
perhaps 5 to 10% of patients. This may reflect the limited
survival of many patients treated so far (Whitehouse, 1985),
and as survival begins to approach or exceed the induction
period of solid tumours, these risks seem likely to increase
(Kaldor et al., 1987). It may be possible to reduce the
carcinogenicity of cancer therapy without loss of efficacy,
either by reduction in dose or duration, or perhaps by
modification of anti-cancer drugs themselves.
There is a need for continuous monitoring of the late
effects of cancer therapy, along the lines of the Late Effects
Study Group for childhood tumours in the USA (Tucker et
al., 1984). Cancer chemotherapy regimes are frequently
revised: the pace of these changes and the complexity of the
regimes themselves will make it difficult to assess any cancer
risks associated with a particular drug or regime unless a
deliberate and systematic effort is made to record second
cancers, and to identify them clearly as such in the hospital
records, from which cancer registrations are ultimately
derived. The number of second primary malignancies
recorded by a single regional cancer registry will usually be
insufficient to enable the risks associated with different
cancer treatment regimes to be clearly distinguished, but a
collaborative group of cancer registries in the UK with an
interest in the late effects of cancer treatment, using both
cohort and case-control methods, would be able to provide
early, precise and unbiased estimates of risk from particular
cytotoxic regimes. This would contribute toward improved
safety of cancer therapy and to reduction of cancer risk in
the population.
We are grateful for advice and assistance from Mr Richard Skeet,
Director of the Thames Cancer Registry.
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